ReviewHepatology communications2021
Impact of COVID-19 in Liver Disease Progression.
Review in Hepatology communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Observational
- Hepatic Decompensation Associated With COVID-19 in a Patient With Alcoholic Liver Cirrhosis: A Case Report.Cureus · 2025Article
- Article
- Review
- Comprehensive clinical and metabolomics profiling of COVID-19 Mexican patients across three epidemiological waves.Frontiers in molecular biosciences · 2025Article
- The impact of the COVID-19 pandemic on non-COVID-associated mortality: A descriptive longitudinal study of UK data.Public health in practice (Oxford, England) · 2024Article
- COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?International journal of molecular sciences · 2024Review
- Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies.World journal of gastroenterology · 2023Review
- Effect of SARS-CoV-2 infection on the liver.World journal of virology · 2023Review
- Outcomes of COVID-19 among patients with liver disease.World journal of gastroenterology · 2023Review
- Clinical characteristics and outcomes of COVID-19 in patients with autoimmune hepatitis: A population-based matched cohort study.World journal of hepatology · 2023Article
- Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.World journal of gastroenterology · 2023Review
- Liver function in transgender persons: Challenges in the COVID-19 era.World journal of clinical cases · 2023Review
- Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditions-Review of the Literature.Medicina (Kaunas, Lithuania) · 2022Review
- Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD).European journal of medical research · 2022Article
- Gastrointestinal and Liver Manifestations in Children with COVID-19 and Their Relationship to Clinical Course.Turkish archives of pediatrics · 2022Article
- Long-term side effects and lingering symptoms post COVID-19 recovery.Reviews in medical virology · 2022Review
- The histologic and molecular correlates of liver disease in fatal COVID-19 including with alcohol use disorder.Annals of diagnostic pathology · 2022Article
- Article
- Rapid Turn From Cirrhosis to Encephalopathy Following COVID-19 Infection: A Cautionary Tale.Cureus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus that causes coronavirus disease 19 (COVID-19), which has infected millions of people worldwide in only a few months. A minority, but significant number, of infected individuals require hospitalization and intensive care. From the start of this new virus pandemic, it was apparent that obese and/or diabetic individuals had a bad prognosis for COVID-19 progression, strongly suggesting an association between liver disease and severe COVID-19. Because chronic liver disease (CLD) is associated with immune dysregulation and inflammation, it is unsurprising that patients with CLD may carry a greater risk of adverse outcomes following SARS-CoV-2 infection. Initial COVID-19 data have also indicated that healthy infected individuals display abnormal liver function tests, suggesting a possible direct implication of SARS-CoV-2 in liver damage. Here we show that COVID-19 affects the liver metabolism and increases the morbidity and mortality of individuals with underlying CLD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.